May 2, 2014 — Anxiety regarding inconclusive test results is real and is only natural. Experts in breast imaging (researchers and clinicians) continue to work to reduce the number of false-positive exams that patients experience and ensure that follow-up exams are as minimally invasive as possible. When women are recalled after an inconclusive mammogram, usually all that is required is an additional mammogram or ultrasound exam.

Only a very small number of screened women, in the range of 1-2 percent, will ultimately receive a needle biopsy as a result of suspicious findings. Physicians continue to refine the reporting process to ensure that patients receive results as quickly as possible. Attention to women's feelings associated with test results is, and should be, a concern for those who provide this care.

Like similar previous studies, Tosteson et al published online April 21, 2014 in the Journal of the American Medical Association (JAMA), proves that patients experience short term anxiety regarding test results and that these feelings rapidly decline over time. The study also shows that there are no measurable effects to women’s health from experiencing a false-positive exam as some have previously claimed.

It is likely that women who have a family history of breast cancer, or those who have already experienced a biopsy as a result of suspicious test results, may be more likely to experience such anxiety. This suggests that we should better inform professionals regarding which women may be more in need of assistance following initially inconclusive results. It may also be that patient anxiety declines more rapidly than previously documented as the act of answering follow-up questionnaires used in such studies may prolong (e.g. “bring back”) any anxiety that had been present.

Past research indicates that nearly all those who experienced a false-positive study support screening and want to know their status. In terms of benefits vs. harms of breast cancer screening, short-term anxiety regarding test results does not equate to dying from breast cancer. The proven benefits of breast cancer screening far outweigh any harm. According to National Cancer Institute data, since mammography screening became widespread in the mid-1980s, the U.S. breast cancer death rate, unchanged for the previous 50 years, has dropped more than 30 percent.

These JAMA findings should, however, remind medical professionals that some women experience adverse effects of a false-positive exam. The medical community should help identify which professionals can help these women cope with and overcome their concerns. The American College of Radiology (ACR) and Society of Breast Imaging (SBI) will provide any input needed to better identify the appropriate professionals to do so.

For more information: www.acr.org, www.sbi-online.org


Related Content

News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
News | RSNA 2025

Nov. 3, 2025 — QT Imaging Holdings has announced that its chief medical officer, Elaine luanow, MD, will host a seminar ...

Time November 04, 2025
arrow
Subscribe Now